1. Home
  2. NRK vs TBPH Comparison

NRK vs TBPH Comparison

Compare NRK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen New York AMT-Free Quality Municipal Income Fund

NRK

Nuveen New York AMT-Free Quality Municipal Income Fund

HOLD

Current Price

$10.53

Market Cap

914.2M

Sector

Finance

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.80

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRK
TBPH
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
914.2M
824.9M
IPO Year
2002
2013

Fundamental Metrics

Financial Performance
Metric
NRK
TBPH
Price
$10.53
$16.80
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$18.40
AVG Volume (30 Days)
246.2K
402.7K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
279.13
EPS
N/A
2.06
Revenue
N/A
$15,386,000.00
Revenue This Year
N/A
$8.46
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.15
Revenue Growth
N/A
N/A
52 Week Low
$9.30
$8.33
52 Week High
$10.60
$21.03

Technical Indicators

Market Signals
Indicator
NRK
TBPH
Relative Strength Index (RSI) 58.77 58.21
Support Level $10.38 $13.41
Resistance Level $10.60 $17.24
Average True Range (ATR) 0.07 0.41
MACD 0.01 0.03
Stochastic Oscillator 70.73 64.71

Price Performance

Historical Comparison
NRK
TBPH

About NRK Nuveen New York AMT-Free Quality Municipal Income Fund

Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: